1-5 of 5
Judit Demeter, MD PhD Dr. Sci
Close
Sort by
Journal Articles

Copanlisib, a PI3K Inhibitor, Demonstrates a Favorable Long-Term Safety Profile in a Pooled Analysis of Patients with Hematologic Malignancies

Pier Luigi Zinzani, MD, Armando Santoro, Luigina Mollica, MD FRCPC, PhD, Sirpa Leppä, MD PhD, George A Follows, MD PhD, Georg Lenz, MD, Won Seog Kim, MD PhD, Arnon Nagler, MD MSc, Panayiotis Panayiotidis, MD, Judit Demeter, MD PhD Dr. Sci, Franck Morschhauser, MD, Javier Munoz, MD MS, FACP, Ashok Miriyala, MD, Alice Benson, PhD, Jose Garcia-Vargas, MD, Barrett H Childs, MD, Martin Dreyling, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4009.
https://doi.org/10.1182/blood-2019-131779
Published: 2019
Journal Articles

Long-Term Efficacy and Safety from the Copanlisib CHRONOS-1 Study in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma

Martin Dreyling, MD PhD, Armando Santoro, MD, Luigina Mollica, MD PhD, Sirpa Leppä, MD, George A Follows, MD PhD, Georg Lenz, Won Seog Kim, MD PhD, Arnon Nagler, MD, Panayiotis Panayiotidis, MD PhD, Judit Demeter, MD PhD Dr. Sci, Muhit Özcan, Marina Kosinova, MD, Krimo Bouabdallah, MD, Franck Morschhauser, MD, Don Stevens, MD, David Trevarthen, MD, Liana Rodrigues, MD, Florian Hiemeyer, MSc, MingLu Wang, MS, Jose Garcia-Vargas, MD, Barrett H. Childs, MD, Pier Luigi Zinzani, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1595.
https://doi.org/10.1182/blood-2018-99-114842
Published: 2018
Journal Articles

Outcomes for Patients with Pre-Existing Diabetes or Hypertension Treated with Copanlisib from the CHRONOS-1 Study in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma

Pier Luigi Zinzani, MD, Armando Santoro, MD, Luigina Mollica, MD FRCPC, PhD, Sirpa Leppä, MD PhD, George A Follows, MD PhD, Georg Lenz, Won Seog Kim, MD PhD, Arnon Nagler, MD, Panayiotis Panayiotidis, MD PhD, Judit Demeter, MD PhD Dr. Sci, Franck Morschhauser, MD, Liana Rodrigues, MD, John Reeves, PhD MS, Florian Hiemeyer, MSc, Ashok Miriyala, MD, Jose Garcia-Vargas, MD, Barrett H. Childs, MD, Martin H. Dreyling, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1613.
https://doi.org/10.1182/blood-2018-99-117063
Published: 2018
Journal Articles

Outcomes for Patients with High-Risk Relapsed or Refractory Indolent B-Cell Lymphoma Treated with Copanlisib in the CHRONOS-1 Study

Armando Santoro, MD, Luigina Mollica, MD PhD, Sirpa Leppa, MD Prof, George A Follows, MD PhD, Georg Lenz, Won Seog Kim, MD PhD, Arnon Nagler, MD, Maria Dimou, MD PhD, Judit Demeter, MD PhD Dr. Sci, Massimo Magagnoli, MD, Liana Rodrigues, MD, Oliver Wirtz, MSc, Florian Hiemeyer, MSc, Li Liu, PhD, Karl Koechert, PhD, Jose Garcia-Vargas, MD, Barrett H Childs, MD, Pier Luigi Zinzani, MD, Martin H. Dreyling, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 395.
https://doi.org/10.1182/blood-2018-99-116715
Published: 2018
Journal Articles

Updated Safety and Efficacy from the Copanlisib CHRONOS-1 Trial in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma: Low Incidence of Late-Onset Severe Toxicities

Martin Dreyling, MD PhD, Armando Santoro, MD, Luigina Mollica, MD PhD, Sirpa Leppa, MD, George Follows, MA, PhD FRCP, FRCPath, BM, BCh, Georg Lenz, Won Seog Kim, MD, Ph. D., Arnon Nagler, MD, Panayiotis Panayiotidis, MD PhD, Judit Demeter, MD PhD Dr. Sci, Muhit Ozcan, MD, Marina Kosinova, MD, Krimo Bouabdallah, MD, Franck Morschhauser, MD PhD, Don A Stevens, MD, David Trevarthen, MD, Massimo Magagnoli, MD, Tatiane Ishida, MD, Cindy Lu, PhD, Florian Hiemeyer, MSc, Ashok Miriyala, MD, Jose Garcia-Vargas, MD, Barrett H. Childs, MD, Pier Luigi Zinzani, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2777.
https://doi.org/10.1182/blood.V130.Suppl_1.2777.2777
Published: 2017